Agent Orange Coronary and Artery Disease
Links shared publicly online about this topic
Cardiology Article | Coronary Artery Disease
mdlinx.com — “Antiplatelet therapy in percutaneous coronary intervention: recent advances in oral antiplatelet agents” View full resource at mdlinx.com
Most Recently Shared on November 15, 2010 at 8:14 am By:
Sandeep Pulim MD Doctor, Health Communicator, and Physician
Antiplatelet therapy in percutaneous coronary intervention: recent advances in oral antiplatelet age... http://bit.ly/dp9TFu #cardiology
Symposier - Dr Robert Mich - Diagnosing and treating Coronary Artery disease
symposier.com — “Uploaded and Shared in Youtube by: AICDHeart Dr. Robert Mich, an expert in interventional cardiology, speaks about the use of catheters, stents, and balloons in diagnosing and treating coronary artery disease. This method is the best means of treating blockages, with a much higher success rate than the use of thrombolytic agents alone. With the use of interventional methods, patients may experience a relief from pain, reduced cardiovascular damage, and quickly return to a full and active life” View full resource at symposier.com
Most Recently Shared on December 8, 2009 at 8:41 pm By:
Symposier Cardiology Cardiology and Health Business
Catheters, Stents and Ballons in diagnosing and treating Coronary Artery Disease with Dr. Robert Mich -->http://bit.ly/71mAoN
ESC | About the ESC | ESC Press Office | ESC Press Releases | E5555 in Japanese patients with acute coronary syndrome or high risk coronary artery disease: the J-LANCELOT trials
escardio.org — “ESC | About the ESC | ESC Press Office | ESC Press Releases | E5555 in Japanese patients with acute coronary syndrome or high risk coronary artery disease: the J-LANCELOT trials” View full resource at escardio.org
Most Recently Shared on August 31, 2010 at 6:55 am By:
European Cardiology Cardiology and Medical Society
E5555 in Japanese patients with ACS or high risk coronary artery disease: the J-LANCELOT trials #ESC10 http://ow.ly/2x9lx
VA to extend benefits to veterans affected by Agent Orange | The American Legion | Veterans Serving Veterans
legion.org — “VA to extend benefits to veterans affected by Agent Orange | The American Legion | Veterans Serving Veterans” View full resource at legion.org
Most Recently Shared on August 17, 2010 at 1:38 pm By:
Susan Scroggins Active Health Library and Health Advocate
Agent orange coronary and artery disease: http://bit.ly/cmRHwV
Family Medicine Article | Anti-Inflammatory Agents, Non-Steroidal
mdlinx.com — “Harmful Effects of NSAIDs among Patients with Hypertension and Coronary Artery Disease” View full resource at mdlinx.com
Most Recently Shared on June 23, 2011 at 11:37 am By:
Sandeep Pulim MD Doctor, Health Communicator, and Physician
Harmful Effects of NSAIDs among Patients with Hypertension and Coronary Artery Disease: American Jo... http://bit.ly/mlkyAi #FamPractice
Cell Point seeks IND for new SPECT agent
healthimaging.com — “Cell Point has submitted to the FDA an investigational new drug (IND) application for a Phase 1b/2 trial of its 99mTc-EC-G diagnostic in assessing patients with coronary artery disease (CAD).” View full resource at healthimaging.com
Most Recently Shared on June 23, 2010 at 1:38 pm By:
Health Imaging & IT Health Magazine
Cell Point seeks IND for new SPECT agent - Cell Point has submitted to the FDA an investigational new drug (IND) app... http://ow.ly/17R20Q
Overall use of blood-thinning agents not improving despite more options
news-medical.net — “Since 1999, stroke survivors have been advised to use aspirin, prescription antiplatelet agents, or prescription anticoagulants to help avoid another stroke. Many large surveys of the U.S. population have reported the use of aspirin for secondary prevention, but commonly combine people with stroke and coronary artery disease, and only rarely report the use of antithrombotic agents other than aspirin.” View full resource at news-medical.net
Most Recently Shared on December 2, 2009 at 8:40 am By:
Stroke News: Overall use of blood-thinning agents not improving despite more options: Since 1999, stroke survivor... http://twurl.nl/gpjzv5
'Major' Finding Sheds Light on How 9p21 Increases CAD Risk - QualityPoint Technologies
qualitypointtech.net — “Research using a new technology has helped to pinpoint why people carrying the 9p21 genetic variant are at higher risk of coronary and other arterial diseases. In the future, it's possible that their risk could be modified with novel anti-inflammatory agents, says one of the researchers. Heartwire” View full resource at qualitypointtech.net
Most Recently Shared on February 11, 2011 at 11:59 pm By:
'Major' Finding Sheds Light on How 9p21 Increases CAD Risk: Research using a new technology has helped to pinpoi... http://bit.ly/eW3zHa
Oral Antiplatelet Agent Brilinta Approved - ONA
oncologynurseadvisor.com — “AstraZeneca announced that Brilinta (ticagrelor), an oral antiplatelet agent, has been approved to reduce the rate of thrombotic cardiovascular events in patients with ACS (unstable angina [UA] non-ST-elevation myocardial infarction [NSTEMI], or ST-elevation myocardial infarction [STEMI]).” View full resource at oncologynurseadvisor.com
Most Recently Shared on July 21, 2011 at 3:58 pm By:
OncologyNurseAdvisor Oncology, Nursing, Medical Education, and Medical Publisher
Oral Antiplatelet Agent Brilinta Approved http://goo.gl/fb/pvzBI
Oral Antiplatelet Agent Brilinta Approved - MPR
empr.com — “AstraZeneca announced that Brilinta (ticagrelor), an oral antiplatelet agent, has been approved to reduce the rate of thrombotic cardiovascular events in patients with ACS (unstable angina [UA] non-ST-elevation myocardial infarction [NSTEMI], or ST-elevation myocardial infarction [STEMI]).” View full resource at empr.com
Most Recently Shared on July 21, 2011 at 3:35 pm By:
MPR News: Oral Antiplatelet Agent Brilinta Approved: AstraZeneca announced that Brilinta (ticagrelor), an oral a... http://bit.ly/n5qZEQ
Reduction In Cardiovascular Death Shown For The First Time With New Oral Antiplatelet Agent Ticagrelor
medicalnewstoday.com — “The presentation of the plato (a study of platelet inhibition and patient outcomes), showed that ticagrelor (brilinta®) reduced the rate of cardiovascular (cv) events (cv death, myocardial inf” View full resource at medicalnewstoday.com
Most Recently Shared on September 1, 2009 at 1:20 pm By:
MedicalNewsToday: Reduction In Cardiovascular Death Shown For The First Time With New Oral: http://bit.ly/UF8lR Full http://bit.ly/73Bfy
Cinacalcet plus vitamin d may decrease vascular calcification in CKD
theheart.org — “Adding the calcimimetic agent cinacalcet to low-dose vitamin-D therapy might lead to less CAC than a flexible-dose regimen of vitaminD only in patients with chronic kidney disease and secondary hyperparathyroidism, according to a new study.” View full resource at theheart.org
Most Recently Shared on April 26, 2010 at 9:26 pm By:
Cinacalcet plus vitamin D may decrease vascular calcification in CKD: Adding the calcimimetic agent cinacalcet to ... http://bit.ly/bXuBUl
Mipomersen, an apolipoprotein B synthesis inhibitor, for lowering of LDL cholesterol concentrations in patients with homozygous familial hypercholesterolaemia: a randomised, double-blind, placebo-controlled trial : The Lancet
thelancet.com — “Mipomersen, an apolipoprotein B synthesis inhibitor, for lowering of LDL cholesterol concentrations in patients with homozygous familial hypercholesterolaemia: a randomised, double-blind, placebo-c...” View full resource at thelancet.com
Most Recently Shared on August 10, 2010 at 1:47 am By:
M Auron MD Doctor, Pediatrician, Internist, and Physician
What is mipomersen - an ApoB synthesis inhibitor - http://bit.ly/asHLUb
The Top 3 resources shared on this topic. More resources.
Key stats and trends about this topic
Related WisdomCards
Related Health Centers
Featuring the top 3 experts for this topic
-
Sandeep Pulim MD
Over 2K medical journal articles & health news summarized and delivered FREE to 35 specialties daily. Oncology, Rheumatology, Cardiology, Neurology, Psychiatry
-
Symposier Cardiology
Symposier.com, the technological platform that will allow you (and your colleagues) to share medical information, and much more with medicine professionals.
-
European Cardiology
The European Society of Cardiology aims to reduce the burden of cardiovascular disease through congresses, surveys, journals and clinical practice guidelines.
Advertisement
